<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009122</url>
  </required_header>
  <id_info>
    <org_study_id>IGEN0206-15</org_study_id>
    <nct_id>NCT04009122</nct_id>
  </id_info>
  <brief_title>Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206</brief_title>
  <official_title>Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Igen BioLab SLU</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Igen BioLab SLU</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A national, multicenter, blind, randomized study of three groups, designed to evaluate the
      impact on the quality of life of IGEN-0206 (IGEN-0206 is a nutritional product, a food) with
      nutritional support + standard treatment versus nutritional support + standard treatment
      versus standard treatment in patients with non-lung cancer metastatic microcytic.

      The standard treatment can include any line of active treatment (chemotherapy, immunotherapy,
      biological therapies or targeted therapies), radiotherapy or nonspecific symptomatic
      treatment.

      It will include 280 patients older than 18 years, who have a life expectancy of less than 9
      months, who will receive or not active treatment.

      After signing the informed consent and confirmation that the subject meets the eligibility
      criteria, those will be randomized (2: 2: 1 ratio) to receive treatment:

        -  Group A (112 patients): patients will receive their standard treatment + nutritional
           support + IGEN-0206

        -  Group B (112 patients): patients will receive their standard treatment + nutritional
           support + placebo.

        -  Group C (56 patients): patients will receive standard treatment. The allocation will be
           random 2: 2: 1 and will be stratified according to ECOG 1 versus 2-3, type of
           oncological treatment (chemotherapy, immunotherapy and / or radiotherapy versus targeted
           therapies versus symptomatic treatment) and type of cancer (squamous versus not flaky).

      The present study seeks to demonstrate that IGEN-0206 improves the quality of life and the
      nutritional status of patients with non-small cell lung cancer. If an improvement in the
      quality of life is achieved, this could impact on a reduction in the number of treatment
      delays / omissions, which could secondarily impact on a response and survival benefit (by
      improving the relative intensity of the active oncological treatment).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Anticipated">December 12, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of IGEN-0206 on quality of life in patients with metastatic lung cancer according to the EORTC QLQ-C30.</measure>
    <time_frame>52 weeks</time_frame>
    <description>The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of IGEN-0206 on quality of life in patients with metastatic lung cancer according to the EORTC QLQ-L13</measure>
    <time_frame>52 weeks</time_frame>
    <description>The QLQ-LC13 incorporates one multi-item scale to assess dyspnoea, and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and haemoptysis.
All of the scales and single-item measures range in score from 0 to 100. A high score for the scales and single items represents a high level of symptomatology or problems</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>52 weeks</time_frame>
    <description>Compare clinical benefits in terms of body mass index (BMI) in the three treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the microbiota</measure>
    <time_frame>12 weeks</time_frame>
    <description>Compare changes in the microbiota profile in terms of microbiota metabolism (faecal samples) in the three treatment arms with proteomics and genomics methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin levels</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the changes in the inflammatory and immune response and to identify immunological biomarkers in the blood with predictive power and prognosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines levels</measure>
    <time_frame>52 weeks</time_frame>
    <description>To evaluate the changes in the inflammatory and immune response and to identify immunological biomarkers in the blood with predictive power and prognosis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Adverse events</measure>
    <time_frame>52 weeks</time_frame>
    <description>To compare adverse events (AEs) in the three treatment groups according to the Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.1.</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time from randomization until the progression of the disease or death from any cause is documented. To compare the efficacy in terms of response and survival among the three arms of the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time elapsed from randomization until death is documented for any reason</description>
  </other_outcome>
  <other_outcome>
    <measure>Objective response rate</measure>
    <time_frame>52 weeks</time_frame>
    <description>The sum of the complete and partial answers</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease control</measure>
    <time_frame>52 weeks</time_frame>
    <description>The sum of stable disease and partial / total response.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of oncological treatment interruptions</measure>
    <time_frame>52 weeks</time_frame>
    <description>To assess tolerability in terms of interruptions or delays in active oncological treatment by adding IGEN-0206</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Quality of Life of Patients</condition>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>IGEN-0206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a sachet after each meal, preferably (3 sachets per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a sachet after each meal, preferably (3 sachets per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IGEN0206</intervention_name>
    <description>Group A</description>
    <arm_group_label>IGEN-0206</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Group B</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who has given informed consent in writing, stating that he / she understands
             the purpose of the study and the procedures it entails, and that he / she agrees to
             participate.

          -  Patient with metastatic non-small cell lung carcinoma confirmed by Pathology.

          -  Expected life expectancy exceeding 12 weeks.

          -  Age ≥18 years.

          -  Functional status of the ECOG 1-3.

          -  Patients who can consume at least 500 ml per day of the nutritional supplement, added
             to their diet.

          -  Patients who do not meet criteria for renal failure: the glomerular filtrate,
             calculated by local formula, must be ≥60 ml / min / 1.73m2.

          -  Patients who are willing to communicate the use of nutritional supplements, including
             oral supplements, vitamins and mineral supplements and / or any food supplement

          -  Patients who are willing to comply with the protocol procedures after having been
             thoroughly informed about the treatment, the procedures, reviewing the study
             methodology and signing the informed consent.

          -  They speak fluent Spanish in order to be able to complete the questionnaires of the
             study.

          -  Potentially fertile women must be negative in a serum pregnancy test performed within
             7 days prior to entry into the study. Potentially fertile patients participating in
             this study should use effective contraceptive methods (eg, abstinence, intrauterine
             device, oral or injectable contraceptives, double-barrier method, or surgical
             sterilization) to prevent pregnancy, which they will begin to use as of signature of
             the informed consent document and whose use will continue until at least 13 weeks
             after the last dose of the study medication has been administered.

        Exclusion Criteria:

          -  Women who are pregnant and / or breast-feeding.

          -  Persistence of the toxicity of a previous treatment (grade&gt; 1 of the NCI-CTCAE v.
             4.03); However, alopecia and sensory neuropathy of grade ≤ 2 are acceptable, as well
             as other side effects that do not endanger patient safety in the opinion of the
             researcher.

          -  Evidence of severe or uncontrolled systemic disease or concomitant process that, in
             the opinion of the investigator, makes the participation of the subject in the study
             inadvisable or compromises compliance with the protocol.

          -  Dementia or mental state significantly altered that could interfere in the
             understanding and granting of informed consent.

          -  Parkinson's disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carmen Perezagua, Physician</last_name>
    <phone>00349115960 00</phone>
    <email>c.perezagua@igenbiotechgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Público Virgen de los Lirios</name>
      <address>
        <city>Alcoi</city>
        <state>Alicante</state>
        <zip>03804</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Pérez, Physician</last_name>
      <phone>0034650657787</phone>
      <email>jpaltozano@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Guirado, Physician</last_name>
      <phone>0034966616250</phone>
      <email>mguiradorisu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elda</name>
      <address>
        <city>Elda</city>
        <state>Alicante</state>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisa Gálvez, Physician</last_name>
      <phone>0034966989109</phone>
      <email>elisagalvezm@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <state>La Coruña</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquín Mosquera, Physician</last_name>
      <phone>0034981178000</phone>
      <email>Joaquin.Mosquera.Martinez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Henares</name>
      <address>
        <city>Coslada</city>
        <state>Madrid</state>
        <zip>28822</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Cervera Calero, Physician</last_name>
      <phone>911912000</phone>
      <email>raquelcervera83@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano Provencio, Physician</last_name>
      <phone>0034911917418</phone>
      <email>mprovencio.ensayosclinicos@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Móstoles</name>
      <address>
        <city>Móstoles</city>
        <state>Madrid</state>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Marrupe, Physician</last_name>
      <phone>0034916648753</phone>
      <email>david.marrupe@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>San Sebastián De Los Reyes</city>
        <state>Madrid</state>
        <zip>28703</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Sereno, Physician</last_name>
      <phone>0034649002612</phone>
      <email>mariasereno75@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Orense</city>
        <state>Ourense</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis Firvida Pérez, Physician</last_name>
      <phone>0034649196690</phone>
      <email>jlfirvidap@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Llatzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Palma</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco García Navalón, Physician</last_name>
      <phone>871202000</phone>
      <email>jfmichelon@hsll.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Sagunto</city>
        <state>Valencia</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Blanco, Physician</last_name>
      <phone>0034962339441</phone>
      <email>sablasmo@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Juan De Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorena Del Río, Physician</last_name>
      <phone>0034965169400</phone>
      <email>lorenadrp@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Moreno, Physician</last_name>
      <phone>957010000</phone>
      <email>almvoncomed2@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begoña Campos, Physician</last_name>
      <phone>0034982295106</phone>
      <email>begona.campos.balea2@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GenesisCare Madrid, Hospital La Milagrosa</name>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis González Larriba, Physician</last_name>
      <phone>0034915644383</phone>
      <email>jglarriba@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sanitas La Zarzuela</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan José Tafalla, Physician</last_name>
      <phone>915858000</phone>
      <email>jjtafalla@sanitas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria María Serrano Montero, Physician</last_name>
      <phone>0034911918000</phone>
      <phone_ext>0034911918000</phone_ext>
      <email>gsm82@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Dómine Gómez, Physician</last_name>
      <phone>915504800</phone>
      <phone_ext>3316</phone_ext>
      <email>manueldomine@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Higuera, Physician</last_name>
      <phone>9172777516</phone>
      <email>oliverhiguera@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Madrid</city>
        <zip>28914</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana López Martín, Physician</last_name>
      <phone>914818000</phone>
      <email>ana5lomar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Galeote Miguel, Physician</last_name>
      <phone>608093004</phone>
      <phone_ext>608093004</phone_ext>
      <email>galeotemiguel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Garde Noguera, Physician</last_name>
      <phone>961976112</phone>
      <email>javiergardenoguera1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Juan-Vidal, Physician</last_name>
      <phone>0034962289579</phone>
      <email>juan_osc@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Artal, Physician</last_name>
      <phone>976765500</phone>
      <email>aartalc@salud.aragon.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Barber MD. Cancer cachexia and its treatment with fish-oil-enriched nutritional supplementation. Nutrition. 2001 Sep;17(9):751-5. Review.</citation>
    <PMID>11527672</PMID>
  </reference>
  <reference>
    <citation>Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998 May;4(5):1087-100. Review.</citation>
    <PMID>9607565</PMID>
  </reference>
  <reference>
    <citation>Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20.</citation>
    <PMID>20493771</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>All collected IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

